NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...
4d
Nektar Therapeutics ( NASDAQ:NKTR ) investors will be delighted, with the company turning in some strong numbers ...
Revenue exceeded analyst estimates by 32%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Looking ahead, ...
Nektar Therapeutics ( (NKTR) ) has released its Q3 earnings. Here is a breakdown of the information Nektar Therapeutics presented to its ...
6d
Nektar Therapeutics (NKTR) extends its cash runway into 2026 with strategic divestitures, despite ongoing financial ...
Nektar Therapeutics today reported financial results for the third quarter ended September 30, 2024. Cash and investments ...
SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Thursday reported a loss of $37.1 million in its third quarter. On a per-share basis, the San Francisco-based company said it ...
Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase ...
Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...
Nektar Therapeutics (NASDAQ:NKTR) is scheduled to announce Q3 earnings results on Thursday, November 7th, after market close.
Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback